News

The deal with Biofisica will enable Sumed to enter the wound healing market and the announcement will see Sumed assume responsibility for sales, marketing and distribution of POSiFECT

Kalypsys will conduct a double-blind, placebo-controlled trial, which will enroll approximately 50 patients at 12-15 centers in the US, to demonstrate proof-of-concept for KD7040 as a treatment for

CovX’s biotherapeutic platform is a technology that links therapeutic peptides to an antibody ‘scaffold’. The peptide targets the disease while the antibody scaffold allows the peptide to remain

The National Association of Chain Drug Stores and the National Community Pharmacists Association sued the Centers for Medicare & Medicaid Services (CMS), asking the court to declare the

This orphan drug designation for Iplex grants Insmed seven years of market exclusivity upon approval for the myotonic muscular dystrophy (MMD) indication. In addition, Insmed is eligible for

The transaction includes an initial upfront payment in addition to committed R&D payments. Ambrx will also be eligible to receive future milestone payments associated with research, development and

The patent is entitled ‘methods for introducing heterologous cells into fish’. In addition, neurons, chondrocytes, renal and hepatic cells can be transplanted in zebrafish and effects of growth

The trial data has been submitted to the Chinese State Food and Drug Administration (SFDA) as the final step in securing agency approval to market Microcyn-based products in

Under the terms of the new agreement, HCL will provide strategic support to Merck’s key IT initiatives. Shami Khorana, president, HCL America, said: “We are delighted to take